Abstract: A system for analyzing documents may (1) retrieve a document filed by a third-party entity including metadata relating to the document; (2) extract media embedded in the document and generate a media file containing the extracted media and a text file containing extracted text; (3) analyze the media file to identify and extract data from within the extracted media; and/or (4) process the text file or a text file generated from the text file to generate text portions from the extracted text. The system may (5) generate embeddings for the text portions; and/or (6) generate a dataset including the text portions, the embeddings, and the metadata. The dataset may be configured to be queried to provide contextual data regarding the document from the text portions. The system may also (7) process the dataset to identify product modifications or new products based on the dataset.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the treatment of a psychiatric or neurological disorder in a patient in need thereof who has anhedonia (lack of pleasure or motivation to pursue rewarding activities) by administering irdabisant or a pharmaceutically acceptable salt thereof, either as a monotherapy, or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorder include major depressive disorder, bipolar depression (such as bipolar I or bipolar II disorders), post-traumatic stress disorder, substance use disorder, anhedonia-related aspects of schizophrenia (e.g., negative symptoms) and schizoaffective disorder (e.g., with mood and/or negative symptoms).

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: Methods and systems for converting computer code are provided. The method may comprise (1) receiving, by one or more processors, a first set of computer code in a first coding language and comprising a plurality of components; (2) generating, by the one or more processors, an interrelationship graph of the plurality of components based upon the first set of computer code, wherein the interrelationship graph represents an interrelationship among the plurality of components; (3) generating, by the one or more processors and based upon the interrelationship graph, a plurality of configuration files associated with at least some of the plurality of components; and/or (4) applying, by the one or more processors, a plurality of templates associated with a second coding language to the plurality of configuration files to generate a second set of computer code in the second coding language.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: An electronic document is provided for display at a first user device associated with a first user. A first input associated with a body portion of the electronic document is received from the first user device of the first user. The first input includes a particular symbol followed by one or more characters that represent a second user. A second input associated with the body portion of the electronic document is received from the first user device of the first user. The second input includes textual input associated with the body portion of the electronic document. The first input associated with the body portion of the electronic document is analyzed to determine one or more user addresses. A message is caused to be sent to a second user device of the second user using the determined one or more user addresses.

Abstract: Content of a first comment corresponding to an electronic document provided by an online document service is received from a first client device associated with a first user. The content of the first comment includes a particular symbol followed by one or more characters that represent a second user. The content of the first comment corresponding to the electronic document is analyzed to determine one or more user addresses. A notification indicating the first comment has been received is sent to a second client device associated with the second user using the determined one or more user addresses.

Abstract: The present disclosure provides a traction device mountable on a vertical surface, such as a wall or door. The traction device can be adjusted by a user to alter the amount of tension applied to the user by a harness of the traction device.

Abstract: A computer-implemented method for coordinating documents between computer systems includes identifying, on a computing device, changes made by a user to a document having a model stored on the computing device, with corresponding models stored on a remote client and a server system; generating from the identified changes, one or more mutations that describe the changes and a one or more locations that correspond to positions in the model where the changes are to be provided; receiving one or more mutations from the server system and transforming the generated mutations using the received mutations; and updating the model stored on the computing device using the transformed mutations.

Abstract: A plurality of comments associated with a document is received, and a representation of the document and a representation of a comment thread comprising the plurality of comments are displayed simultaneously on a user device. In one embodiment, a first comment is received from a first user and a second comment is received from a second user. The comment thread may be stored. Systems and apparatus are also disclosed.

Abstract: A chewable delivery pouch including a chewable composition containing cannabis. An interior volume of the chewable pouch is filled with a composition having a quantity of mint, coconut oil and cannabis plant extracts. In some embodiments, the coconut oil is replaced with another bedewer, such as vegetable glycerin. The chewable delivery pouch allows a user's saliva and dissolved molecules in the sputum to pass between the interior volume of the pouch and a user's mouth.

Abstract: A computer-implemented method for coordinating documents between computer systems includes identifying, on a computing device, changes made by a user to a document having a model stored on the computing device, with corresponding models stored on a remote client and a server system; generating from the identified changes, one or more mutations that describe the changes and a one or more locations that correspond to positions in the model where the changes are to be provided; receiving one or more mutations from the server system and transforming the generated mutations using the received mutations; and updating the model stored on the computing device using the transformed mutations.

Abstract: A tabletted chewing gum sweet characterised in that it comprises at least two integral parts, a first integral part comprising a compressed gum base and a tablet base material, and a second integral part comprising a compressed tablet base material. In the mouth, the tablet exhibits a first crunchy stage which changes to a second chewing gum stage.